Abstract
While the ribosome is a common target for antibiotics, challenges with crystallography can impede the development of new bioactives using structure-based drug design approaches. In this study we exploit common structural features present in linezolid-resistant forms of both methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) to redesign the antibiotic. Enabled by rapid and facile cryoEM structures, this process has identified (S)-2,2-dichloro-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (LZD-5) and (S)-2-chloro-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl) acetamide (LZD-6), which inhibit the ribosomal function and growth of linezolid-resistant MRSA and VRE. The strategy discussed highlights the potential for cryoEM to facilitate the development of novel bioactive materials.
Original language | English |
---|---|
Pages (from-to) | 527-231 |
Number of pages | 5 |
Journal | ChemMedChem |
Volume | 14 |
Issue number | 5 |
DOIs | |
Publication status | Published - 5 Mar 2019 |
Keywords
- antibiotic resistance
- cryoEM
- linezolid
- structure-based drug design
Equipment
-
Ramaciotti Centre for Cryo-Electron Microscopy
Georg Ramm (Manager), Viola M.J. Oorschot (Operator), Simon Andrew Crawford (Operator), Hariprasad Venugopal (Operator), Joan Marea Clark (Operator) & Gediminas Gervinskas (Operator)
Office of the Vice-Provost (Research and Research Infrastructure)Facility/equipment: Facility